Brumbaugh v. Sandoz Pharmaceutical Corp.

77 F. Supp. 2d 1153, 1999 U.S. Dist. LEXIS 20824, 1999 WL 1104539
CourtDistrict Court, D. Montana
DecidedSeptember 27, 1999
DocketCV 97-088-GF-DWM
StatusPublished
Cited by16 cases

This text of 77 F. Supp. 2d 1153 (Brumbaugh v. Sandoz Pharmaceutical Corp.) is published on Counsel Stack Legal Research, covering District Court, D. Montana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Brumbaugh v. Sandoz Pharmaceutical Corp., 77 F. Supp. 2d 1153, 1999 U.S. Dist. LEXIS 20824, 1999 WL 1104539 (D. Mont. 1999).

Opinion

ORDER

MOLLOY, District Judge.

This case is about a postpartum drug that allegedly causes significant medical problems in some women who use it. The crux of the issue before me is the Daubert question: should plaintiffs expert be allowed to testify.

Defendant Sandoz moves the Court for summary judgment on the issue of medical causation since the expected testimony of plaintiffs medical causation expert is unreliable and not based on accepted scientific methodology. The matter was fully briefed by the parties. An evidentiary hearing was set and oral argument was heard on September 3, 1999. Dr. Iffy, the challenged expert, was not present and did not testify. My findings as to the basis of his opinions are based on sworn deposition testimony he has given in this and related cases. For the reasons set out below, and for the reasons I stated in the record, the motion for summary judgment is granted and judgment is entered for the defendant.

*1155 I.Background Facts

On April 4, 1994, plaintiff was twenty three weeks pregnant when she was attacked by her boyfriend and admitted to the hospital suffering from a traumatically induced premature separation of her placenta. Her baby was delivered by cesarean section but died two days later due to its prematurity. Brumbaugh’s treating OB/GYN prescribed Parlodel to reduce her breast engorgement and associated pain. 1 She was released from the hospital four days later.

On April 11, plaintiff attended her baby’s funeral. A short time later she suffered a seizure. She was treated and released from the hospital, but suffered an additional seizure on April 12 so she was once again hospitalized. Brumbaugh’s OB/GYN recommended to the treating neurosurgeon that Parlodel be discontinued due to the fact that the Physician’s Desk Reference indicated that seizure had been reported in temporal association with Parlodel’s use.

Parlodel’s active ingredient prevents lactation from occurring by blocking the hormone which causes it. With respect to circulation, the drug’s primary effects on blood vessels are to cause vasodilation (widening of blood vessels) and to lower blood pressure. Seizure side effects are commonly associated with vasoconstric-tors, which produce the opposite effect on blood vessels and raise blood pressure.

Defendant points to five studies (two of them epidemiological studies, which study the causal relationship between an agent and disease) which show no statistically significant relationship between Parlodel and seizure. In fact, defendant states that several of the studies suggest the opposite — that Parlodel, as a vasodilator, actually exerts a protective effect against postpartum stroke.

In his expert report, the challenged expert, Dr. Iffy, opines that he believes Par-lodel has caused a chronic seizure condition in plaintiff. To support his opinions, he relies not on epidemiological studies but on anecdotal case reports and his theory that Parlodel can act as a vasospastic agent instead of a vasodilator.

II.Legal Standard

Rulings on the admissibility of expert testimony under Fed.R.Evid. 702 are in the sound discretion of the trial court. General Elec. Co. v. Joiner, 522 U.S. 136, 118 S.Ct. 512, 517, 139 L.Ed.2d 508 (1997). Precluding plaintiffs expert directly 'impacts defendant’s motion for summary judgment brought pursuant to Fed.R.Civ.P. 56(c). The Supreme Court holds that “the plain language of Rule 56(c) mandates the entry of summary judgment, after adequate time for discovery and upon motion, against a party who fails to make a showing sufficient to establish the existence of an element essential to that party’s case.” Celotex Corp. v. Catrett, 477 U.S. 317, 322, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986).

III.Discussion

The issue is whether the expected testimony .of plaintiffs expert Dr. Iffy has sufficient scientific reliability to be admissible under the standards for expert testimony set out in Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993). Without Dr. Iffy’s testimony, plaintiff will be unable to offer evidence on causation at trial so her claim fails as a matter of law without the proof.

*1156 The threshold questions for admissibility of expert scientific testimony are whether the proffered testimony reflects scientific knowledge and whether it will assist the trier of fact. Daubert, 509 U.S. at 592, 113 S.Ct. 2786. In exercising the “gate keeper” function of deciding whether to admit such testimony, a Court must make “a preliminary assessment of whether the reasoning or methodology underlying the testimony is scientifically valid and of whether that reasoning or methodology properly can be applied to the facts in issue.” Id., at 592-593, 113 S.Ct. 2786.

A “key question” which courts must answer as they undertake their review is whether the technique or theory being advanced by the expert is testable or has been tested, the methodology of which is “what distinguishes science from other fields of human inquiry.” Id., at 593, 113 S.Ct. 2786. None of the five studies cited by defendant and designed to analyze the causal relationship between Parlodel and hypertension, stroke, and seizure supports Dr. Iffy’s theory that Parlodel generally causes seizure. The plaintiff criticizes certain aspects of these studies, but she produced no epidemiological study, or other reliable scientific proof that does make the causal link between Parlodel and her condition, or any related condition. Plaintiffs lawyers attack on defendant’s studies does not meet the law’s requirements. She must come forward with reliable scientific evidence of her own to defeat a summary judgment motion when her case is based on the expert’s proof.

The predicate of Dr. Iffy’s opinion is that Parlodel caused plaintiffs injury because it involved the temporal association between her prescription and her injury as well as his review of case reports and adverse drug events. The case reports were generated through other litigation with which Dr. Iffy was associated. Adverse drug events (ADE’s) are temporal associations between a drug’s administration and an unexpected physical reaction. In this case, Dr. Iffy admits that ADE’s do not demonstrate a causal link but instead represent coincidence. Case reports and ADE’s are compilations of occurrences, and have been rejected as reliable scientific evidence supporting expert opinion so as to meet the requirements set forth in Daubert. Jones v. United States, 933 F.Supp. 894, 899 (N.D.Cal.1996), aff'd 127 F.3d 1154

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Slatowski v. SIG SAUER, INC.
E.D. Pennsylvania, 2024
In re Mirena Ius Levonorgestrel-Related Prods. Liab. Litig.
341 F. Supp. 3d 213 (S.D. Illinois, 2018)
Hyman & Armstrong, P.S.C. v. Gunderson
279 S.W.3d 93 (Kentucky Supreme Court, 2008)
In Re W.R. Grace & Co.
355 B.R. 462 (D. Delaware, 2006)
In Re Meridia Products Liability Litigation
328 F. Supp. 2d 791 (N.D. Ohio, 2004)
Soldo v. Sandoz Pharmaceuticals Corp.
244 F. Supp. 2d 434 (W.D. Pennsylvania, 2003)
Bonnie Joyce Rider v. Sandoz Pharmaceuticals
295 F.3d 1194 (Eleventh Circuit, 2002)
Hollander v. Sandoz Pharmaceuticals Corp.
289 F.3d 1193 (Tenth Circuit, 2002)
Caraker v. Sandoz Pharmaceuticals Corp.
188 F. Supp. 2d 1026 (S.D. Illinois, 2001)
Siharath v. Sandoz Pharmaceuticals Corp.
131 F. Supp. 2d 1347 (N.D. Georgia, 2001)
Globetti v. Sandoz Pharmaceuticals, Corp.
111 F. Supp. 2d 1174 (N.D. Alabama, 2000)
Glastetter v. Novartis Pharmaceuticals Corp.
107 F. Supp. 2d 1015 (E.D. Missouri, 2000)
Nelson v. American Home Products Corp.
92 F. Supp. 2d 954 (W.D. Missouri, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
77 F. Supp. 2d 1153, 1999 U.S. Dist. LEXIS 20824, 1999 WL 1104539, Counsel Stack Legal Research, https://law.counselstack.com/opinion/brumbaugh-v-sandoz-pharmaceutical-corp-mtd-1999.